CL
NBIX icon

CSS LLC’s Neurocrine Biosciences NBIX Stock Holding History

CSS LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-5,000
Closed -$426K – 1261
2021
Q4 		$426K Buy
+5,000
New +$460K 0.02% 702
2020
Q2 		– Sell
-100
Closed -$9K – 741
2020
Q1 		$9K Sell
100
-1,800
-95% -$176K ﹤0.01% 579
2019
Q4 		$204K Sell
1,900
-8,900
-82% -$932K 0.01% 502
2019
Q3 		$973K Buy
+10,800
New +$1.01M 0.06% 218

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CSS LLC's NBIX Position: Q1 2026 in Review

CSS LLC increased its Neurocrine Biosciences (NBIX) stake by 329% in Q1 2026, buying an estimated $707K and bringing the position to 6,950 shares worth $916K. The position accounts for 0.04% of the portfolio, ranked #365.

CSS LLC first reported a position in NBIX in Q1 2025 and has held it in 3 quarters since. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • CSS LLC held 6,950 shares of Neurocrine Biosciences worth $916K as of Q1 2026.
  • CSS LLC bought 5,330 Neurocrine Biosciences shares in Q1 2026, an estimated $707K.
  • Neurocrine Biosciences made up 0.04% of CSS LLC's portfolio in Q1 2026, its #365 holding.
  • CSS LLC first reported a position in Neurocrine Biosciences in Q1 2025 and has held it in 3 quarters since.
  • 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on CSS LLC's 13F filing for Q1 2026, filed 15 May 2026.